• Farnesyl Alcohol Azide: Evidence Boundaries

  2026-10-17

  APExBIO lists Farnesyl Alcohol Azide under SKU C4380, but the available product information provides no structural record, properties, mechanism, measurement principle, or identity-matched research evidence. The name supports only a cautious nomenclature-based description; it does not establish chemical connectivity, reactivity, biological activity, or performance in any assay.

• Farnesyl Alcohol Azide: Evidence and Scope

  2026-10-16

  APExBIO identifies Farnesyl Alcohol Azide as catalog SKU C4380, but the available product information provides no description, structural characterization, mechanism, assay context, or identity-matched research evidence. The material can therefore be discussed only as a catalog-level chemical designation, not as a mechanistically validated reagent or research-performance claim.

• Farnesyl Alcohol Azide: Evidence Boundaries

  2026-10-16

  The APExBIO catalog metadata identifies Farnesyl Alcohol Azide as product C4380, but provides no description, structural record, analytical characterization, mechanism, assay context, or identity-matched research evidence. The product name supports only a limited nomenclature-level interpretation; it does not establish molecular connectivity, reactivity, measurement performance, or biological application.

• ALC-0159: Identity, Mechanism, and Evidence

  2026-10-15

  ALC-0159 is documented by APExBIO as a PEG-conjugated lipid excipient for lipid nanoparticle formulations used in mRNA delivery. The product description establishes identity and intended formulation context, but not product-specific performance, molecular parameters, or research outcomes. Related PET-imaging summaries clarify how protein-expression measurements differ from tracking nanoparticles or mRNA, while providing no evidence that the cited study used ALC-0159.

• Mc-Val-Cit-PABC-PNP: Evidence and Scope

  2026-10-15

  Mc-Val-Cit-PABC-PNP is cataloged by APExBIO as a cathepsin B-cleavable ADC peptide linker intended to support lysosome-associated payload release. The available evidence is a product description rather than an identity-matched research study, so its molecular specifications and intended mechanism can be summarized, but cleavage performance, selectivity, conjugate behavior, and clinical relevance cannot be independently established from the cited material.

• NAD+: Identity, Mechanism, and Evidence Boundaries

  2026-10-14

  This source-attributed overview distinguishes the documented identity and biochemical roles of APExBIO’s NAD+ product from research evidence that is not available for the named material. It explains what NAD+ redox and enzyme-associated measurements can establish, while defining the limits of claims about signaling, supplementation, and biological performance.

• KRAS Condensates in Colon Cancer

  2026-10-14

  A 2026 Cell study proposes that farnesylation-dependent KRAS condensates organize KRAS processing and signaling in colon cancer. The reported findings support a mechanistic connection between C185 farnesylation, RCE1 clustering, plasma-membrane trafficking and tumor growth, while remaining limited by the preclinical evidence summarized here and by incomplete reporting of model details and effect sizes.

• GERD Mechanism Study: Findings and Limits

  2026-10-13

  A 2024 preclinical study reports that berberine combined with evodiamine reduced reflux-associated esophageal injury and inflammatory signaling in rat and human epithelial-cell models. The findings support a possible TAS2R38/TRPV1-related mechanism, but they do not establish clinical efficacy, receptor-specific action in patients, or therapeutic relevance for Hoechst 33342.

• Angiotensin I/II (1-5): Evidence and Scope

  2026-10-13

  The APExBIO catalog identifies Angiotensin I/II (1-5) as the Asp-Arg-Val-Tyr-Ile peptide fragment and places it within conceptual renin-angiotensin system research. No matched research paper was available, so the product description does not establish biological activity, mechanism, or research outcomes independently.

• Verapamil and the TXNIP–Bone Turnover Link

  2026-10-12

  A 2025 study examined whether verapamil’s reported suppression of TXNIP could be relevant to osteoporosis. Combining a Chinese genetic association analysis with cell-based mechanistic work and an ovariectomy-induced mouse model, the authors linked TXNIP-related signaling to bone turnover and reported reduced bone loss after verapamil exposure in mice. The findings are hypothesis-generating rather than evidence of clinical efficacy.

• Sodium Oxamate: What the ICH Study Shows

  2026-10-12

  A 2026 mouse study suggests that lactate-linked H3K18 lactylation in microglia may support white-matter repair after intracerebral hemorrhage. Its divergent findings with Oxamate and p300/CBP inhibition caution against treating LDH-A inhibition, lactate reduction, and histone-lactylation blockade as interchangeable—and do not establish cancer or clinical efficacy.

• Klotho mRNA and Cellular Rejuvenation: An Appraisal

  2026-10-11

  A 2026 preclinical study reports that engineered Klotho mRNA reduced senescence-associated phenotypes in aged and Klotho-deficient induced mesenchymal stem cells. The evidence is promising but remains limited to cellular models, short-term molecular and functional readouts, and the study record supplied here does not establish therapeutic benefit in animals or humans.

• PFPD Nanorods Activate STING via Nuclear DNA Damage

  2026-10-10

  The 2024 Journal of Controlled Release study presents PFPD, nuclear-targeted chimeric peptide nanorods that combine a photosensitizer with the STING agonist DMXAA (Vadimezan). By linking light-triggered nuclear DNA damage to cGAS/STING signaling, the platform enhanced innate immune activation and suppressed lung metastatic tumors in the reported preclinical models.

• Pyridostatin: From G4 Stabilization to Evidence

  2026-10-09

  Pyridostatin and Pyridostatin TFA are useful chemical probes for studying G-quadruplex biology. This article explains how to interpret their effects across telomere, cancer, and TDP-43 research while separating direct evidence from carefully bounded scientific inference.

• Single-Cell Insights into A. baumannii Biofilms

  2026-10-09

  A 2026 journal pre-proof uses single-cell RNA sequencing and pseudotemporal analysis to examine how Acinetobacter baumannii transitions from planktonic growth to mature biofilm states. The study reports increasing transcriptional heterogeneity, metabolic divergence, stress adaptation, nutrient-scavenging programs, and a trajectory-associated state transition. Its findings are valuable for hypothesis generation, but they do not by themselves establish causality, clinical relevance, or validated therapeutic targets.

7868 records 1/525 page Next 12345 下5页 Last page